PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Mirati Therapeutics, Inc.® (“Mirati”). With the completion of the acquisition, Mirati shares have ceased trading on the NASDAQ Global Select Market and Mirati is now a wholly owned subsidiary of Bristol Myers Squibb..

普林斯顿，新泽西州——（商业新闻短讯）——百时美施贵宝（纽约证券交易所：BMY）今天宣布，它已成功完成对Mirati Therapeutics，Inc.®（“Mirati”）的收购。收购完成后，米拉蒂的股票已停止在纳斯达克全球精选市场交易，米拉蒂现在是百时美施贵宝的全资子公司。。

“The closing of the Mirati transaction is a significant milestone in our efforts to further diversify our oncology portfolio and strengthen our pipeline in the latter half of the decade and beyond,” said Chris Boerner, Ph.D., Chief Executive Officer, Bristol Myers Squibb. “Mirati’s incredibly talented employees have built a strong portfolio of assets and capabilities that are highly complementary with BMS’.

百时美施贵宝首席执行官ChrisBoerner博士说：“Mirati交易的完成是我们努力进一步多样化我们的肿瘤学投资组合并在十年后半期及以后加强我们的渠道的一个重要里程碑。”。“米拉蒂极具天赋的员工建立了强大的资产和能力组合，与BMS高度互补”。

We welcome them and look forward to working together to leverage BMS’ global scale and resources to deliver more treatments for cancer patients, faster.”.

我们欢迎他们，并期待着共同努力，利用BMS的全球规模和资源，更快地为癌症患者提供更多的治疗。”。

Through this transaction, BMS has added commercialized lung cancer medicine KRAZATI (adagrasib) to its oncology portfolio as well as several promising clinical assets, including a potential first-in-class MTA-cooperative PRMT5 inhibitor in Phase 1 development, and a leading KRAS and KRAS enabling program with two candidates in Phase 1 development..

通过这项交易，BMS将商业化的肺癌药物KRAZATI（adagrasib）添加到了其肿瘤学组合中，以及一些有前途的临床资产，包括第一阶段开发中潜在的一流MTA合作PRMT5抑制剂，以及领先的KRAS和KRAS使能计划，第一阶段开发中有两名候选人。。

The transaction is expected to be treated as a business combination and to be dilutive to Bristol Myers Squibb’s non-GAAP earnings per share by approximately $0.35 per share in 2024.

预计该交易将被视为企业合并，并将在2024年稀释百时美施贵宝的非公认会计准则每股收益约0.35美元。

Advisors

顾问

Evercore Inc. and Morgan Stanley & Co. LLC are serving as financial advisors to Bristol Myers Squibb, and Kirkland & Ellis LLP is serving as legal counsel. Centerview Partners LLC is serving as financial advisor to Mirati, and Skadden, Arps, Slate, Meagher & Flom LLP is serving as legal counsel.

Evercore Inc.和Morgan Stanley＆Co.LLC担任百时美施贵宝的财务顾问，Kirkland＆Ellis LLP担任法律顾问。Centerview Partners LLC担任Mirati的财务顾问，Skadden、Arps、Slate、Meagher&Flom LLP担任法律顾问。

About Bristol Myers Squibb

关于百时美施贵宝

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram..

百时美施贵宝是一家全球生物制药公司，其使命是发现、开发和提供创新药物，帮助患者战胜严重疾病。有关百时美施贵宝的更多信息，请访问BMS.com或在LinkedIn、Twitter、YouTube、Facebook和Instagram上关注我们。。

Cautionary Statement Regarding Forward-Looking Statements

关于前瞻性声明的警示声明

This communication contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the acquisition of Mirati by Bristol Myers Squibb. These statements may be identified by the fact they use words such as “should,” “could,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe,” “will” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance, although not all forward-looking statements contain such terms.

本通讯包含经修订的《1933年证券法》第27A节和经修订的《1934年证券交易法》第21E节所指的“前瞻性声明”，其中涉及百时美施贵宝收购米拉蒂。这些报表可以通过使用“应该”、“可以”、“期望”、“预期”、“估计”、“目标”、“可能”、“项目”、“指导”、“打算”、“计划”、“相信”、“将会”等词语以及与未来经营或财务业绩相关的其他具有类似含义和表达的词语和术语来识别，尽管并非所有前瞻性声明都包含此类术语。

All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. These statements are only predictions, and such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations.

所有不属于历史事实陈述的陈述都是或可能被视为前瞻性陈述。这些声明只是预测，此类前瞻性声明基于当前的预期，涉及固有的风险和不确定性，包括可能延迟、转移或改变其中任何一项的因素，并可能导致实际结果和结果与当前的预期产生重大差异。

No forward-looking statement can be guaranteed. Actual results may differ materially from current expectations because of numerous risks and uncertainties including with respect to (i) the risk that the expected benefits or synergies of the acquisition will not be realized, (ii) the risk that legal proceedings may be instituted related to the merger agreement, and (iii) unanticipated difficulties or expenditures relating to the transaction, the response of business partners and competitors to the consummation of the transaction and/or potential difficulties in employee retention as a result of the consummation of the transaction.

不能保证前瞻性声明。由于存在许多风险和不确定性，实际结果可能与当前预期存在重大差异，包括（i）收购的预期收益或协同效应无法实现的风险，（ii）可能提起与合并协议有关的法律诉讼的风险，以及（iii）与交易有关的意外困难或支出，商业合作伙伴和竞争对手对交易完成和/或交易完成导致员工留任潜在困难的反应。

Forward-looking statements in this communica.

本公报中的前瞻性声明。

corporatefinancial-news

企业财经新闻